Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present a corporate overview followed by a question and answer session with investors on June 23, 2015 at 10:30 a.m. ET during the JMP Securities Life Sciences Conference.
A live webcast and replay of the session can be accessed by visiting the “Calendar of Events” section on the “Investors” page of Enanta’s website at www.enanta.com. The replay webcast will be available following the presentation and will be archived for approximately 30 days.
About Enanta
Enanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases. Enanta is
discovering, and in some cases developing, novel inhibitors designed for
use against the hepatitis C virus (HCV). These inhibitors include
members of the direct acting antiviral (DAA) inhibitor classes –
protease (partnered with AbbVie), NS5A, and nucleotide polymerase – as
well as a host-targeted antiviral (HTA) inhibitor class targeted against
cyclophilin. Enanta’s lead protease inhibitor, paritaprevir, is part of
AbbVie’s recently approved HCV treatment regimens. In addition, Enanta
has a preclinical program in non-alcoholic steatohepatitis, or NASH,
which is a condition that results in liver inflammation and damage
caused by a buildup of fat in the liver.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150616005157/en/